$GILD Company News The market puts a few feathers in its

New Post Public Reply Private Reply Replies (0) Message Board

Jan 28, 2014 at 12:55 PM

$GILD Company News

The market puts a few feathers in its cap 1:58 p.m. Jan. 23, 2014 - The Trading Deck
Are the prevailing technicals bullish, or bearish? 11:55 a.m. Jan. 17, 2014 - Michael Ashbaugh
U.S. stocks drop on Goldman, Citi; Nasdaq edges up 4:08 p.m. Jan. 16, 2014 - Laura Mandaro
Nu Skin sinks on China probe; Best Buy hits 6-month low 4:05 p.m. Jan. 16, 2014 - Sue Chang
S&P 500 drops from record, but Nasdaq ekes out gain: Stock market live blog recap 4:02 p.m. Jan. 16, 2014 - blogs.marketwatch.com
Speculators turn the heat up to ‘soft boil’ 3:55 p.m. Jan. 16, 2014 - The Trading Deck
Mounting optimism for hepatitis C drug boosts Gilead to lead S&P 500 3:09 p.m. Jan. 16, 2014 - Russ Britt
Earnings boost Micron, drag on Container Store 4:25 p.m. Jan. 8, 2014 - Sue Chang
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
3 top trades for 2014 6:01 a.m. Dec. 30, 2013 - Jeff Reeves
Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - Russ Britt
Twitter hits record; Campbell, Starbucks head south 4:25 p.m. Dec. 10, 2013 - Sue Chang
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:19 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski

Biotechs - especially Biogen, Celgene, Gilead - have further to rise, DB says 57 min ago - Seeking Alpha
Idenix Pharma CEO Speaks On Plans for the $107 Million Just Raised 10:22 a.m. Today - TheStreet.com
Big cap biotech pushed at Deutsche 9:12 a.m. Today - Seeking Alpha
Is The Healthcare Sector Pulling Back Or Crashing? 5:40 a.m. Today - Seeking Alpha
Cramer's Mad Money - We Are In Reset Mode (1/27/14) 5:06 a.m. Today - Seeking Alpha
Growth Portfolio Super Bowl: Gilead Vs. Polaris 12:09 a.m. Today - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Market Reset 8:33 p.m. Jan. 27, 2014 - TheStreet.com
CHMP Positive on Bayer's Riociguat - Analyst Blog 4:30 p.m. Jan. 27, 2014 - Zacks.com
Top 2013 Drug Approvals: Pharma Stocks 3:58 p.m. Jan. 27, 2014 - Seeking Alpha
Obamacare Boosts Health Funds 11:26 a.m. Jan. 27, 2014 - TheStreet.com
Payers revel against Gilead over cost of hepatitis C pill 7:14 a.m. Jan. 27, 2014 - Seeking Alpha
Payers rebel against Gilead over cost of hepatitis C pill 7:14 a.m. Jan. 27, 2014 - Seeking Alpha
Liver Drug Race: Intercept Pharma Vs. Rivals 7:24 p.m. Jan. 26, 2014 - Seeking Alpha
Weekly CFO Sells Highlight: Forest Laboratories Inc, U.S. ... 4:06 p.m. Jan. 26, 2014 - GuruFocus.com
5 New Drugs That Could Be Blockbusters in 2014 3:42 a.m. Jan. 25, 2014 - Barrons.com
BMY Pummeled After Earnings, But Bristol-Myers Squibb Stock Still a Buy 10:20 a.m. Jan. 24, 2014 - InvestorPlace.com
Amidst Huge Unknowns, Conatus Pharmaceuticals Worth A Closer Look 9:30 a.m. Jan. 24, 2014 - Seeking Alpha
Biotech Bull Market Key Trend No. 1: 5 Large Cap Biopharmas Plus 2 11:39 a.m. Jan. 23, 2014 - Seeking Alpha
Gilead Sciences: Will It Double Your Money Again In 2014? 2:22 a.m. Jan. 23, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: The Market's Wild Ride 8:18 p.m. Jan. 22, 2014 - TheStreet.com

Gilead Announces Executive Promotions 5:00 p.m. Jan. 27, 2014 - BusinessWire - BZX
European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection 9:09 a.m. Jan. 17, 2014 - BusinessWire - BZX
Acceptance of NDA for Review, Acquisitions of Development Rights, Earnings Release Schedulesm and New Leaders - Research Report on Gilead, Lilly, Allergan, Incyte, and Varian Medical Systems 8:00 a.m. Jan. 16, 2014 - PR Newswire - PRF
U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Biotoscana agrees to acquire United Medical to expand commercial presence in Brazil and create a leading regional specialty pharmaceutical company in South America 1:15 a.m. Jan. 13, 2014 - BusinessWire - BZX
Gilead Sciences to Present at the 32nd Annual JPMorgan Healthcare Conference on Monday, January 13 5:00 p.m. Jan. 10, 2014 - BusinessWire - BZX
Retirement Announcements, Stock Price Movements, and Scheduled Conferences Presentations - Research Report on Gilead, Aegerion, Celldex, Alnylam, and Ironwood 8:00 a.m. Jan. 9, 2014 - PR Newswire
Stock Price Movements, Conference Presentation Schedules, and Expanded Sharing of Clinical Data - Research Report on Gilead, Express Scripts, Sanofi, Agilent, and Kythera Biopharma 8:00 a.m. Jan. 8, 2014 - PR Newswire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Notable Buzzers: Apple Inc, Stereotaxis Inc, Tiger Oil and Energy Inc, Gilead Sciences Inc 11:00 a.m. Jan. 7, 2014 - ACCESSWIRE
Gilead Sciences' Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire 4:29 p.m. Jan. 6, 2014 - BusinessWire
Critical Alerts For Trina Solar, Gilead Sciences, Priceline, Akamai, and Anglogold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 2, 2014 - PR Newswire
Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune 8:00 a.m. Dec. 26, 2013 - PR Newswire
Clinical Trial Results, Stock Movements, Grants & Donations, and Drug Resubmissions - Research Report on Gilead, WellPoint, Zoetis, Teleflex, and Orexigen 8:00 a.m. Dec. 23, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Gilead Sciences Tops List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 8:00 a.m. Dec. 19, 2013 - Marketwire
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients 8:30 a.m. Dec. 18, 2013 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
Critical Insider Analysis: MGM Resorts International, Groupon Inc, Gilead Sciences, Barrick Gold Corporation 9:30 a.m. Dec. 17, 2013 - ACCESSWIRE
FDA Approvals, Dividends, Promoting Diversity, Result Publications and Acquisitions - Research Report on Gilead, St. Jude Medical, Cigna, Pharmacyclics, and LifePoint 8:00 a.m. Dec. 17, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Succession Planning in Turmoil: Only 42% Ready

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Compass Unveiled: Power Revolution in Private Equity

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Cracking the Code of America's Delivery Addiction

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Machine Grabs Prime Dallas Property Amid Apartment Boom

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....